Metabolic Disorders and Male Hypogonadotropic Hypogonadism
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Several studies highlight that testosterone deficiency is associated with, and predicts, an increased risk of developing metabolic disorders, and, on the other hand, is highly prevalent in obesity, metabolic syndrome and type-2 diabetes mellitus. Models of gonadotropin releasing hormone deficiency, and androgen deprivation therapy in patients with prostate cancer, suggest that hypogonadotropic hypogonadism might contribute to the onset or worsening of metabolic conditions, by increasing visceral adiposity and insulin resistance. Nevertheless, in functional hypogonadism, as well as in late onset hypogonadism, the relationship between hypogonadotropic hypogonadism and metabolic disorders is bidirectional, and a vicious circle between the two components has been documented. The mechanisms underlying the crosstalk between testosterone deficiency and metabolic disorders include increased visceral adipose tissue and insulin resistance, leading to development of metabolic disorders, which in turn contribute to a further reduction of testosterone levels. The decrease in testosterone levels might be determined by insulin resistance-mediated and, possibly, pro-inflammatory cytokine-mediated decrease of sex hormone binding globulin, resulting in a temporary increased free testosterone available for aromatization to estradiol in visceral adipose tissue, followed by a subsequent decrease in free testosterone levels, due to the excess of visceral adipose tissue and aromatization; by a direct inhibitory effect of increased leptin levels on Leydig cells; and by a reduced gonadotropin secretion induced by estradiol, inflammatory mediators, leptin resistance, and insulin resistance, with the ultimate determination of a substantial hypogonadotropic hypogonadism. The majority of studies focusing on the effects of testosterone replacement therapy on metabolic profile reported a beneficial effect of testosterone on body weight, waist circumference, body mass index, body composition, cholesterol levels, and glycemic control. Consistently, several interventional studies demonstrated that correction of metabolic disorders, in particular with compounds displaying a greater impact on body weight and insulin resistance, improved testosterone levels. The aim of the current review is to provide a comprehensive overview on the relationship between hypogonadotropic hypogonadism and metabolism, by clarifying the independent role of testosterone deficiency in the pathogenesis of metabolic disorders, and by describing the relative role of testosterone deficiency and metabolic impairment, in the context of the bidirectional relationship between hypogonadism and metabolic diseases documented in functional hypogonadotropic hypogonadism. These aspects will be assessed by describing metabolic profile in men with hypogonadotropic hypogonadism, and androgenic status in men with metabolic disorders; afterwards, the reciprocal effects of testosterone replacement therapy and corrective interventions on metabolic derangements will be reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Brain Insulin Receptor in Control of Body Weight and Reproduction
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235 · cited 1×
“On the other side, experimental animal models demonstrated that insulin exerts a stimulatory action on hypothalamic GnRH neurons, which results in gonadotropin release, therefore suggesting that IR associated with metabolic disorders might reduce gonadotropin secretion and promote hypogonadism (31).”
BackgroundDing, E. L., Song, Y., Malik, V. S., & Liu, S. (2006) · JAMA · doi:10.1001/jama.295.11.1288 · Cited by 1,354
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920 · cited 1×
“A population-based prospective cohort study on 702 middle-aged men without MetS or T2-DM at baseline demonstrated that men with total testosterone (TT) or calculated free testosterone (FT) or sex hormone binding globulin (SHBG) levels in the lowest quartile had an increased risk of developing MetS, when compared with…”
BackgroundInvestigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 1×
“In particular, one case-control study on 36 hypogonadal men, comprising 29 men with Hypo-H (20 with known cause and 9 idiopathic), and 7 men with Hyper-H, aged 22–68 years (median age 53 years), highlighted that TRT with 100mg intramuscular testosterone enanthate once per week for 18 months significantly decreased tot…”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“A double-blind randomized crossover study on 24 hypogonadal men (2 Hypo-H, 8 Hyper-H, 14 mixed) with T2-DM demonstrated that TRT with 200mg intramuscular testosterone propionate every 2 weeks for 3 months significantly reduced HbA1c and glucose levels, WC and waist/hip ratio, and significantly improved HOMA-IR, in pat…”
BackgroundPrevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767 · cited 1×
“A large study on 2098 men demonstrated that the prevalence of HypoH, with decreased TT, FT, and SHBG, was significantly higher in T2-DM patients, rather than patients without T2-DM (69).”
BackgroundChanges in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 1×
“Moreover, differently from classical MetS, ADT-induced Hypo-H is associated with increased, rather than decreased, high-density lipoprotein (HDL) levels, and a preferential increase in subcutaneous adipose tissue, rather than VAT (47).”
BackgroundIsidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02339.x · Cited by 695
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631 · cited 7×
“Moreover, additional studies highlighted that the association of testosterone deficiency with metabolic disorders frequently occurs in a clinical context of Hypo-H, and that Hypo-H is frequently reported in metabolic disorders, such as obesity, IR, MetS, and T2-DM (15, 19, 20).”
BackgroundResultInfluential
Cited by
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
Huang, G., Pencina, K. M., Li, Z., Basaria, S., Bhasin, S., Travison, T. G., Storer, T. W., Harman, S. M., & Tsitouras, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02545 · Cited by 40
Functional hypogonadism among patients with obesity, diabetes, and metabolic syndrome
Louters, M., Pearlman, M., Solsrud, E., & Pearlman, A. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00496-7 · Cited by 32
Metabolism of testosterone during weight loss in men with obesity
Van de Velde, F., Deventer, K., Van Gansbeke, W., Van Eenoo, P., Van Renterghem, P., Fiers, T., Reyns, T., Kaufman, J. M., Van Nieuwenhove, Y., & Lapauw, B. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105851 · Cited by 17
Kaltsas, A., Dimitriadis, F., Zachariou, A., Koukos, S., Chrisofos, M., & Sofikitis, N. (2026) · Cells · doi:10.3390/cells15020158 · Cited by 12
“Baseline gonadotropin levels and sex hormone-binding globulin (SHBG) provide additional context by distinguishing primary testicular failure from secondary hypogonadotropic dysfunction and by reflecting metabolic influences on androgen bioavailability [135].”
Metadata
- Authors
- Pivonello, R., Menafra, D., Riccio, E., Garifalos, F., Mazzella, M., de Angelis, C., & Colao, A.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-25
- Volume
- 10
- Pages
- 345-345
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2963380087
- Cited by
- 143
- References
- 60
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.